Covid-19: is omicron less lethal than delta?

Lorenzo-Redondo, Ramón; Ozer, Egon A.; Hultquist, Judd F.

doi:10.1136/bmj.o1806

Cited by 29 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But in 2022 we see sufficient decrease in mortality and much lower CFR values. This can be explained as a positive effect of vaccinations (the global VC values tend to some saturation in 2022, see green line), lower pathogenicity of the Omicron strain (which began to spread widely at the end of 2021, [16,17]), as well as the influence of natural immunity [18]. Green, yellow and magenta lines respectively show VC j , BC j , R j values listed in [8].…”

Section: Resultsmentioning

confidence: 99%

Endemic characteristics of SARS-CoV-2 infection

Nesteruk

2023

Preprint

View full text Add to dashboard Cite

The fourth year of the COVID-19 pandemic without decreasing trends in the global numbers of new daily cases, high numbers of circulating SARS-CoV-2 variants and re-infections together with pessimistic predictions for the Omicron wave duration force studies about the endemic stage of the disease. The global trends were illustrated with the use the accumulated numbers of laboratory-confirmed COVID-19 cases and deaths, the percentages of fully vaccinated people and boosters and the results of calculation of the effective reproduction number provided by Johns Hopkins University. The modified SIR model showed the presence of unsteady equilibrium. The global numbers of new daily cases will range between 300 thousand and one million, daily deaths – between one and 3.3 thousand.

show abstract

Section: Resultsmentioning

confidence: 99%

Endemic characteristics of SARS-CoV-2 infection

Nesteruk

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Until the emergence of the Delta variant, 15–50% of older adults with COVID-19 progressed to severe disease, and 1 in 10 patients died [ 28 , 29 ]. In contrast, the mortality and disease progression rate related to COVID-19 has decreased dramatically since the emergence of the Omicron variant, even among older adults [ 30 , 31 , 32 ]. In addition to the early administration of an antiviral agent to patients at high risk of severe disease, the expansion of healthcare resources for socially vulnerable groups is critical for the management of COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting

Mutoh

Umemura

Nishikawa

et al. 2023

Viruses

View full text Add to dashboard Cite

Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their effectiveness in older adults and those at high risk of disease progression. This retrospective single-center observational study assessed and compared the outcomes of COVID-19 treated with MOV and NMV/r in a real-world community setting. We included patients with confirmed COVID-19 combined with one or more risk factors for disease progression from June to October 2022. Of 283 patients, 79.9% received MOV and 20.1% NMV/r. The mean patient age was 71.7 years, 56.5% were men, and 71.7% had received ≥3 doses of vaccine. COVID-19-related hospitalization (2.8% and 3.5%, respectively; p = 0.978) or death (0.4% and 3.5%, respectively; p = 0.104) did not differ significantly between the MOV and NMV/r groups. The incidence of adverse events was 2.7% and 5.3%, and the incidence of treatment discontinuation was 2.7% and 5.3% in the MOV and NMV/r groups, respectively. The real-world effectiveness of MOV and NMV/r was similar among older adults and those at high risk of disease progression. The incidence of hospitalization or death was low.

show abstract

“…Airborne pathogens are mainly contracted within the respiratory pathways, especially through the nose, since airborne particles are mostly filtered within the nasal airway [ 61 ]. The important role played by the nasal epithelia in COVID-19 has been further magnified after emergence of the many Omicron sublineages, which exhibit highly efficient replication within the nasal tissue [ 62 ]. Mucosal immunity in this district, either developing after acute SARS-CoV-2 infection or COVID-19 vaccination, may hence represent one of the most efficient deterrents for preventing direct contact between the virus and the host cells.…”

Section: Discussionmentioning

confidence: 99%

Improving Nasal Protection for Preventing SARS-CoV-2 Infection

Nocini

Henry

Mattiuzzi³

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Airborne pathogens, including SARS-CoV-2, are mainly contracted within the airway pathways, especially in the nasal epithelia, where inhaled air is mostly filtered in resting conditions. Mucosal immunity developing after SARS-CoV-2 infection or vaccination in this part of the body represents one of the most efficient deterrents for preventing viral infection. Nonetheless, the complete lack of such protection in SARS-CoV-2 naïve or seronegative subjects, the limited capacity of neutralizing new and highly mutated lineages, along with the progressive waning of mucosal immunity over time, lead the way to considering alternative strategies for constructing new walls that could stop or entrap the virus at the nasal mucosa surface, which is the area primarily colonized by the new SARS-CoV-2 Omicron sublineages. Among various infection preventive strategies, those based on generating physical barriers within the nose, aimed at impeding host cell penetration (i.e., using compounds with mucoadhesive properties, which act by hindering, entrapping or adsorbing the virus), or those preventing the association of SARS-CoV-2 with its cellular receptors (i.e., administering anti-SARS-CoV-2 neutralizing antibodies or agents that inhibit priming or binding of the spike protein) could be considered appealing perspectives. Provided that these agents are proven safe, comfortable, and compatible with daily life, we suggest prioritizing their usage in subjects at enhanced risk of contagion, during high-risk activities, as well as in patients more likely to develop severe forms of SARS-CoV-2 infection.

show abstract

Covid-19: is omicron less lethal than delta?

Cited by 29 publications

References 12 publications

Endemic characteristics of SARS-CoV-2 infection

Endemic characteristics of SARS-CoV-2 infection

Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting

Improving Nasal Protection for Preventing SARS-CoV-2 Infection

Contact Info

Product

Resources

About